Report
Lilly’s Jaypirca wins FDA approval for previously untreated CLL and SLL
STAT describes Jaypirca as a first-line therapy for chronic lymphocytic leukemia; the approval also covers small lymphocytic lymphoma.
TLDR
STAT reports that the FDA approved Eli Lilly’s Jaypirca for previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). STAT describes it as a first-line CLL therapy.
Combined views
1.2K
1 Source, first seen ago
2 likes1 reposts